San Pablo, CA, United States of America

Kimberly Marlen

This inventor holds 3 USPTO granted patents. Top assignee: Metabolex, Inc.. Active years: 2006-2009.


% Patents Active = 33.3

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2006-2009

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Kimberly Marlen

Introduction

Kimberly Marlen is a prominent inventor based in San Pablo, CA (US). She has made significant contributions to the field of biotechnology, particularly in the area of diabetes research. With a total of 3 patents to her name, her work focuses on innovative methods for diagnosing and treating diabetes.

Latest Patents

One of her latest patents involves compositions and methods of using apoptosis signaling kinase related kinase (ASKRK). This invention provides nucleic acid and polypeptide sequences related to ASKRK and outlines methods for identifying modulators of this kinase. These modulators have potential applications in the treatment of diabetes and delaying its onset. Additionally, her patent includes methods for diagnosing diabetes or pre-diabetes and making prognoses based on the detection of ASKRK nucleic acids and proteins.

Career Highlights

Kimberly Marlen is currently associated with Metabolex, Inc., where she continues to advance her research and innovations. Her work has garnered attention for its potential impact on diabetes management and treatment.

Collaborations

Some of her notable coworkers include Jeffrey D Johnson and Yun-Ping Zhou, who contribute to her research endeavors and collaborative projects.

Conclusion

Kimberly Marlen's innovative work in the field of diabetes research exemplifies the importance of scientific advancements in healthcare. Her contributions through her patents are paving the way for new diagnostic and therapeutic approaches to this prevalent condition.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…